Work

Overall survival analysis from a randomized phase II study of axitinib with or without dose titration for first-line metastatic renal cell carcinoma.

Year: 2015

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2015.33.15_suppl.4545

Authors: Brian I. Rini, Yoshihiko Tomita, Bohuslav Melichar, Takeshi Ueda, Viktor Grünwald, Mayer N. Fishman, Hirotsugu Uemura, Mototsugu Oya, A H. Bair, Glen Andrews, Dmitri Pavlov, Eric Jonasch

Institutions: Cleveland Clinic, Yamagata University, Yamagata University Hospital, Palacký University Olomouc, Chiba Cancer Center, Medizinische Hochschule Hannover, Moffitt Cancer Center, Kindai University, Keio University, Pfizer (United States), The University of Texas MD Anderson Cancer Center

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4237323457

Cites:

Cited by: 2

Related to: 10